Literature DB >> 21491165

Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluation of 46 consecutive patients.

Terence C Chua1, Ihssan Al-Alem, Akshat Saxena, Winston Liauw, David L Morris.   

Abstract

BACKGROUND: Surgical cytoreduction and intraperitoneal chemotherapy is increasingly accepted as an effective treatment modality for mucinous appendiceal neoplasm. For the majority of patients with low-grade histology, outcomes have been encouraging. The survival of patients with neoplasms of malignant character is protracted and this study was designed to evaluate the effectiveness of this surgical strategy on outcomes.
METHODS: Forty-six consecutive patients with mucinous and nonmucinous appendiceal cancer with peritoneal dissemination were studied. Clinicopathological and treatment related factors were obtained from a prospective database. The study's end points of disease-free survival (DFS) and overall survival (OS) were analyzed using the Kaplan-Meier method.
RESULTS: The median DFS and OS after cytoreduction were 20.5 and 56.4 months respectively. Five-year overall survival rate was 45%. Five independent factors associated with DFS and OS were identified through a multivariate analysis: age (DFS p = 0.001, OS p = 0.002), completeness of cytoreduction (DFS p = 0.001, OS p = 0.003), previous chemotherapy treatment (DFS p = 0.021), CA 199 levels (DFS p = 0.013), and tumor grade (OS p = 0.005).
CONCLUSIONS: Cytoreductive surgery and intraperitoneal chemotherapy may achieve long-term survival in appendiceal malignancies with peritoneal dissemination for which the predictors of outcomes identified through this study may tailor the disease management to commit patients early toward this successful surgical strategy.

Entities:  

Mesh:

Year:  2011        PMID: 21491165     DOI: 10.1245/s10434-011-1714-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

Review 1.  Surgical treatment of peritoneal carcinomatosis: current treatment modalities.

Authors:  Yakup Kulu; Beat Müller-Stich; Markus W Büchler; Alexis Ulrich
Journal:  Langenbecks Arch Surg       Date:  2013-11-19       Impact factor: 3.445

Review 2.  Outcome following incomplete surgical cytoreduction combined with intraperitoneal chemotherapy for colorectal peritoneal metastases.

Authors:  Roisin Mary Heaney; Conor Shields; Jurgen Mulsow
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

3.  Carbohydrate antigen 19-9 (CA 19-9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy.

Authors:  Ju-Li Koh; Winston Liauw; Terence Chua; David L Morris
Journal:  J Gastrointest Oncol       Date:  2013-06

4.  Hyperthermic intraperitoneal chemotherapy with melphalan: a summary of clinical and pharmacological data in 34 patients.

Authors:  Lana Bijelic; Paul H Sugarbaker; O Anthony Stuart
Journal:  Gastroenterol Res Pract       Date:  2012-07-03       Impact factor: 2.260

Review 5.  The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions.

Authors:  Madeleine C Strach; Sarah Sutherland; Lisa G Horvath; Kate Mahon
Journal:  Ther Adv Med Oncol       Date:  2022-07-23       Impact factor: 5.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.